Data gathered: November 27
Alternative Data for ACELYRIN
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 447 | Sign up | Sign up | Sign up |
| Twitter Mentions | 24,686 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About ACELYRIN
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company is headquartered in Agoura Hills, California.
| Price | $4.57 |
| Target Price | Sign up |
| Volume | 246,030 |
| Market Cap | $475M |
| Year Range | $3.86 - $7.78 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
 |
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Price Target from BrokeragesNovember 27 - ETF Daily News |
 |
Acelyrin (NASDAQ:SLRN) Price Target Raised to $8.00 at HC WainwrightNovember 18 - ETF Daily News |
 |
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ...November 13 - Yahoo |
 |
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call TranscriptNovember 13 - SeekingAlpha |
 |
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsNovember 13 - Yahoo |
ACELYRIN : Reports Third Quarter 2024 Financial Results and Recent Highlights Form 8 KNovember 13 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 23M | -23M | -49M | 0 | -0.490 |
| Q2 '24 | 0 | 17M | -17M | -86M | -93M | -0.860 |
| Q1 '24 | 0 | 25M | -25M | -35M | -83M | -0.360 |
| Q4 '23 | 0 | 22M | -22M | -95M | -105M | -0.970 |
| Q3 '23 | 0 | 20M | -20M | -84M | -94M | -0.870 |
Insider Transactions View All
| Becker Daniel J. filed to sell 2,999 shares at $6.9. July 19 '24 |
| Lin Shao-Lee filed to sell 1,577,374 shares at $6.6. April 3 '24 |
| Lin Shao-Lee filed to sell 1,587,335 shares at $7.6. February 22 '24 |
| Lin Shao-Lee filed to sell 1,603,036 shares at $7.4. January 4 '24 |
| Oyston Ronald filed to buy 26 shares at $18. May 11 '23 |
Similar companies
Read more about ACELYRIN (SLRN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of ACELYRIN?
The Market Cap of ACELYRIN is $475M.
What is the current stock price of ACELYRIN?
Currently, the price of one share of ACELYRIN stock is $4.57.
How can I analyze the SLRN stock price chart for investment decisions?
The SLRN stock price chart above provides a comprehensive visual representation of ACELYRIN's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ACELYRIN shares. Our platform offers an up-to-date SLRN stock price chart, along with technical data analysis and alternative data insights.
Does SLRN offer dividends to its shareholders?
As of our latest update, ACELYRIN (SLRN) does not offer dividends to its shareholders. Investors interested in ACELYRIN should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ACELYRIN?
Some of the similar stocks of ACELYRIN are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.